Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 31, 2015 5:00 AM ET


Company Overview of Sorbent Therapeutics, Inc.

Company Overview

Sorbent Therapeutics, Inc., a biopharmaceutical company, develops therapies for cardiovascular and renal diseases. The company focuses on the development of nonabsorbed polymeric drugs to satisfy clinical needs in cardiovascular and renal markets, such as congestive heart failure, end-stage renal disease, chronic kidney disease, and hypertension. Its CLP platform offers an array of non-absorbed polymers that are chemically and bio-designed to contribute or sequester targeted ions and fluid to deliver prescribed therapeutic actions in the gastro intestinal tract. The company’s products include CLP 1001 that removes potassium, sodium, and fluid; CLP 1004 that removes potassium; and CLP 1003 th...

710 Lakeway Drive

Suite 290

Sunnyvale, CA 94085

United States

Founded in 2005





Key Executives for Sorbent Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 54
Co-Founder and Chairman of Medical Advisory Board
Co-Founder and Director
Age: 77
Senior Vice President of Development
Chief Business Officer
Compensation as of Fiscal Year 2015.

Sorbent Therapeutics, Inc. Key Developments

Sorbent Therapeutics Appoints Two New Board Members

Sorbent Therapeutics, Inc. announced the appointment of Jay Shepard and William D. Waddill to the company's Board of Directors. Mr. Shepard currently serves as an Executive Partner at Sofinnova Ventures and has more than 32 years of commercial and company building experience in the specialty pharmaceutical and biotechnology industry. Mr. Waddill is the Senior Vice President, Chief Financial Officer of privately held Calithera Biosciences, with more than 20 years of biotechnology experience focused on corporate financial matters.

Sorbent Therapeutics, Inc. Announces the Completion of Enrollment of 275 Patients with Heart Failure in the Company's Phase 2b STEPWISE Clinical Trial of CLP-1001

Sorbent Therapeutics, Inc. announced the completion of enrollment of 275 patients with heart failure in the company's Phase 2b STEPWISE clinical trial of CLP-1001. The Phase 2b randomized, double-blind, multi-center STEPWISE trial is intended to evaluate the safety, tolerability and efficacy of CLP-1001 therapy in addressing the signs and symptoms of fluid overload in heart failure patients. Sorbent expects to announce topline results from the STEPWISE clinical study during the third quarter of 2014. Proceeds from the financing will be used to support continued development of CLP-1001 and general corporate operations. CLP-1001 is a cross-linked polyelectrolyte polymer intended to selectively bind to and remove excess water and sodium in the GI tract. As the fastest-growing cardiac disease in the U.S., heart failure results in more than one million hospitalizations each year. Fluid overload is estimated to be involved in 80% of heart failure hospitalizations due to the additional pressure that excess water and sodium place on the heart and kidneys. Sorbent completed a Phase 2a study with CLP-1001 in 100 patients that demonstrated favorable effects on many of the signs and symptoms of heart failure in patients with advanced symptomatic heart failure and chronic kidney disease.

Sorbent Therapeutics, Inc. Appoints Tom O'Neil as Chief Financial Officer

Sorbent Therapeutics, Inc. announced that Tom O'Neil has joined the company as Chief Financial Officer. Mr. O'Neil brings more than 15 years of industry experience to Sorbent. In this role, he will oversee Sorbent's financial operations, reporting directly to Detlef Albrecht, M.D., Sorbent's President and Chief Executive Officer. Mr. O'Neil has more than 15 years of finance and operations experience in start-ups through large public companies. Previously, Mr. O'Neil was Vice President, Finance & Administration for ChemGenex Pharmaceuticals.

Similar Private Companies By Industry

Company Name Region
NeilMed Pharmaceuticals, Inc. United States
Dr. Reddy's Laboratories Inc. United States
Jason Properties, LLC United States
Tummy Company, Inc. United States
Phoenix Global Supply Group, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sorbent Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at